ArticleCancer diagnosis & prognosis
Palatal Solitary Plasmacytoma: A Case Report on Post-radiotherapy Challenges.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Plasmacytomas are neoplastic proliferations of plasma cells, usually presenting as solitary lesions distinct from multiple myeloma (MM). Solitary plasmacytomas in the oral cavity and head and neck are very rare, with limited data on clinical course and treatment response. Case Report: A 78-year-old woman presented with a solitary plasmacytoma on the palate. Imaging ruled out bone or systemic involvement. Pathology showed positivity for CD138, lambda light chain, CD79a, MUM1, Ki-67 (10-15%), and amyloid deposits. Although the patient received definitive radiation therapy (50 Gy/25 fractions), residual disease remained. At the patient's request, six cycles of systemic chemotherapy with daratumumab, lenalidomide, and dexamethasone (DRd) were administered, leading to further shrinkage without complete response. Conclusion: This rare case of solitary plasmacytoma showed residual disease post definitive radiotherapy. In those residual tumors, close long-term monitoring is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.